Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options
Conditions
Brief summary
This is a single center, single arm, open-label phase II study to determine the efficacy and safety of a single infusion of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR/4-1BB) co-stimulatory domains (referred to as CART-19 cells) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Inclusion criteria are designed to include adult patients aged greater than 18 with B cell ALL, relapsed or refractory, with no available curative treatment options (such as autologous or allogeneic stem cell transplantation) who have limited prognosis (greater than 12 weeks survival expectancy) with currently available therapies. The study product is CART-19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCR:41BB administered by a single i.v. infusion of 1 to 5 x 108 transduced CAR T cells.
Interventions
BIOLOGICALCART-19
CART-19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCR:41BB administered by a single i.v. infusion of 1 to 5 x 10\^8 transduced CAR T cells
Sponsors
University of Pennsylvania
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed informed consent form must be obtained prior to any study procedure * Relapsed or refractory B-cell ALL 1. 1st or greater BM relapse OR 2. Any marrow relapse after allogeneic HSCT and \> 100 days from transplant OR 3. For patients with refractory disease: i. \< 60 years old that have not achieved a CR after \> 2 or more chemotherapy regimens ii. \>60 years old that have not achieved a CR after 1 prior chemotherapy regimen d. Patients with Ph+ ALL are eligible if they have failed tyrosine kinase inhibitor therapy * Documentation of CD19 tumor expression in bone marrow or peripheral blood by flow cytometry within 3 months of screening. * Adequate organ function defined as: 1. Creatinine \< 1.6 mg/dl 2. ALT/AST \< 3x upper limit of normal range 3. Direct bilirubin \<2.0 mg/dl 4. Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea, pulse oxygen \> 92% on room air, and DLCO \> 40% (corrected for anemia if clinically appropriate) 5. Left Ventricle Ejection Fraction (LVEF) ≥ 40% confirmed by ECHO/MUGA * Bone marrow with ≥ 5% lymphoblasts * Male or female age ≥ 18 years * A ECOG Performance Status that is either 0 or 1 * No contraindications for leukapheresis. Retreatment Inclusion Criteria * Performance Status 0-1 * Adequate organ system function including: * Creatinine \< 1.6 mg/dl * ALT/AST \< 3x upper limit of normal * Total Bilirubin \< 2.0 mg/dl * Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea, pulse oxygen \> 92% on room air, and DLCO \> 40% (corrected for anemia if clinically appropriate) * Left Ventricular Ejection Fraction ≥ 40% * No contraindications for leukapheresis (if required for retreatment) * Gives voluntary informed consent for retreatment
Exclusion criteria
* Isolated extramedullary disease relapse * Active hepatitis B or active hepatitis C * Class III/IV cardiovascular disability according to the New York Heart Association Classification * HIV infection * Active acute or chronic graft-versus-host disease (GVHD) or requirement of immunosuppressant medications for GVHD within 4 weeks of enrollment. * Concurrent use of systemic steroids or chronic use of immunosuppressant medications. Recent or current use of inhaled steroids is not exclusionary. For additional details regarding use of steroid and immunosuppressant medications. * Active CNS involvement by malignancy. Note: Patients with history of CNS disease that has been effectively treated will be eligible provided that treatment was \>4 weeks before enrollment * Pregnant or nursing (lactating) women, female study participants of reproductive potential must have a negative serum or urine pregnancy test within 48 hours before infusion * Participation in a prior investigational study within 4 weeks prior to enrollment or longer if required by local regulation. Participation in non-therapeutic research studies is allowed. * Patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system. Retreatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Complete Remission Rate at Day 28 After CART-19 Therapy | 28 Days | Overall Complete Remission Rate (ORR) which includes complete remission (CR) and CR with incomplete blood count recovery (CRi) at Day 28. Overall Complete Remission Rate = CR+ CRi |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Best Overall Response | from the start of the treatment until death, last follow up, relapse or start of new anticancer therapy, whichever comes first, assessed up to 12 months | For the secondary efficacy objectives for this study, the number of patients were computed with a best overall disease response of CR or CRi, where the best overall disease response is defined as the best disease response recorded from the start of the treatment until death, last follow up, relapse or start of new anticancer therapy, whichever comes first. |
Countries
United States
Participant flow
Recruitment details
Patients were identified through the clinical practices of the investigator or sub-investigators and through referrals from outside hospitals and physicians. No direct-to-patient advertising was performed.
Participants by arm
| Arm | Count |
|---|---|
| Arm1 phase II study to determine the efficacy & safety of a single infusion of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as CART-19 cells) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
CART-19: CART-19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCR:41BB administered by a single i.v. infusion of 1 to 5 x 10\^8 transduced CAR T cells
CART-19: As of June 2014, dose was reduced to a single dose of 1-5x10\^7 CART-19 cells.
CART-19: In the protocol amendment in November 2014, the dose remained 1-5 x 10\^7 CART-19 cells, but was revised to be administered via split dosing: 10% on Day 1, 30% on Day 2, 60% on Day 3.
CART-19: In the protocol amendment in May 2015, the dose was changed to 1-5 x 10\^8 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x10\^7), 30% on Day 2 (3x10\^7-1.5x10\^8), 60% on Day 3 (6x10\^7-3x10\^8 | 30 |
| Total | 30 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Death | 10 |
| Overall Study | Disease Progression | 15 |
| Overall Study | New Cancer Therapy | 8 |
| Overall Study | Physician Decision | 3 |
| Overall Study | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | Arm1 |
|---|---|
| Age, Continuous | 39.6 years STANDARD_DEVIATION 16.34 |
| Age, Customized >=18 to <40 Years | 18 participants |
| Age, Customized >=40 to <65 Years | 10 participants |
| Age, Customized >=65 Years | 2 participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 28 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race/Ethnicity, Customized Asian | 1 participants |
| Race/Ethnicity, Customized Caucasian | 28 participants |
| Race/Ethnicity, Customized Other | 1 participants |
| Sex: Female, Male Female | 10 Participants |
| Sex: Female, Male Male | 20 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 30 / 42 |
| other Total, other adverse events | 30 / 30 |
| serious Total, serious adverse events | 30 / 30 |
Outcome results
Primary
Overall Complete Remission Rate at Day 28 After CART-19 Therapy
Overall Complete Remission Rate (ORR) which includes complete remission (CR) and CR with incomplete blood count recovery (CRi) at Day 28. Overall Complete Remission Rate = CR+ CRi
Time frame: 28 Days
Population: Out of 42 enrolled, only 30 patients were infused with CART-19 product. 30 infused patients were considered for outcome measure.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arm1 | Overall Complete Remission Rate at Day 28 After CART-19 Therapy | Complete Remission (CR) | 8 Participants |
| Arm1 | Overall Complete Remission Rate at Day 28 After CART-19 Therapy | CR with incomplete blood count recovery (CRi) | 10 Participants |
| Arm1 | Overall Complete Remission Rate at Day 28 After CART-19 Therapy | No Response | 6 Participants |
| Arm1 | Overall Complete Remission Rate at Day 28 After CART-19 Therapy | Unknown | 6 Participants |
Secondary
Best Overall Response
For the secondary efficacy objectives for this study, the number of patients were computed with a best overall disease response of CR or CRi, where the best overall disease response is defined as the best disease response recorded from the start of the treatment until death, last follow up, relapse or start of new anticancer therapy, whichever comes first.
Time frame: from the start of the treatment until death, last follow up, relapse or start of new anticancer therapy, whichever comes first, assessed up to 12 months
Population: Out of 42 enrolled, only 30 patients were infused with CART-19 product. 30 infused patients were considered for outcome measure.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arm1 | Best Overall Response | Complete Remission (CR) | 10 Participants |
| Arm1 | Best Overall Response | CR with incomplete blood count recovery (CRi) | 1 Participants |
| Arm1 | Best Overall Response | No Response | 8 Participants |
| Arm1 | Best Overall Response | Unknown | 11 Participants |